The Durham, North Carolina-based cell biology tech firm said the acquisition was supported by a concurrent Series B financing led by Telegraph Hill Partners.
Fluxion is a California-based company that develops products such as liquid biopsy systems and cellular analysis tools for drug discovery and diagnostic applications.